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Abstract. Background: The prognostic role of the ex vivo drug
resistance profile has not yet been proved in childhood acute
myeloid leukemia (AML). The aim of the study was the
analysis of the impact of the ex vivo drug resistance profile in a
cohort of 44 children with AML undergoing hematopoietic stem
cell transplantation (HSCT). Patients and Methods:
Myeloblasts for drug resistance testing were obtained from the
bone marrow either on diagnosis or at relapse, before the HSCT
procedure and were tested by the MTT assay. Results: Children
who relapsed after transplantation showed higher ex vivo
resistance of the leukemic blasts to etoposide, mercaptopurine,
thioguanine, fludarabine, mitoxantrone and treosulfan than
those who stayed in remission. Despite being nondiscriminative,
the combined ex vivo drug resistance profile to fludarabine,
treosulfan and etoposide (FTE score) was the strongest
prognostic factor by multivariate analysis. Conclusion: The
combined drug resistance profile to fludarabine, treosulfan and
etoposide may be useful for better stratification of children with
AML undergoing stem cell transplantation or to indicate the
necessity for additional post-transplant therapy.
The combined ex vivo drug resistance profile to prednisolone,
vincristine and L-asparaginase (PVA score) has prognostic
value in childhood de novo acute lymphoblastic leukemia
(ALL) (1, 2). The results of therapy for childhood acute
myeloid leukemia (AML) differ from those of ALL. The
development of drug resistance is the limiting factor in the
therapy of AML (3). In pediatric AML, in spite of several
reports (3-5), the prognostic role of the ex vivo drug
resistance profile has not yet been proved, with one possible
exception of the prognostic role of sensitivity to cytarabine
(6), while this relationship has been confirmed in adult AML
(7). Apart from one study of children and adults with acute
leukemia (8), no data are available regarding the possible
role of drug resistance in children undergoing hematopoietic
stem cell transplantation (HSCT). In this study, the
prognostic value of the ex vivo drug resistance profile in
pediatric AML patients undergoing HSCT was analyzed. 
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Patients and Methods
Patients. Fourty-four children (28 male, 16 female) with AML,
including 20 in complete remission (CR1) and 24 relapsed patients,
aged 0.7-17 years (median 10 years), who underwent HSCT, were
included in the study. Patients with favourable cytogenetics of the
leukemic blasts and those suffering early transplant-related
mortality were not included in the study. The patients received
myeloablative conditioning based on busulfan (n=32), treosulfan
(n=8), fractionated total body irradiation (FTBI, n=3), or
cyclophosphamide (n=1). Thymoglobulin was administered before
unrelated or haploidentical HSCT. The source of the graft was
matched sibling donor (n=20), matched unrelated donor (n=9),
autologous (n=12) or mismatched family donor (n=3). The
patients were followed up for a median of 2.5 (range 0.2-4.3) years.
Fresh myeloblasts for drug resistance testing were obtained from
the bone marrow either on diagnosis or at relapse, before HSCT,
and were processed as described previously (9). Only samples with
at least of 70% of myeloblasts were included in the study. The
study was approved by the local Bioethical Committee and written
informed consent was obtained from all patients and their parents.
Drug resistance profile. The drugs used in the study are listed in
Table I. The cytotoxicity of the tested compounds to leukemic cells
was measured by the MTT assay, as described previously (10). All
experiments were performed in duplicate. The cytotoxicity was
expressed as IC50, the inhibitory concentration for 50% of the cells.
According to the median cytotoxicity for each tested drug, all the
patients were scored as resistant (score 2) or sensitive (score 1) to
this drug. The FTE score was defined as the sum of three
respective score values for fludarabine, treosulfan and etoposide;
thus the FTE score ranged from 3 to 6. An FTE score of 3-4 was
regarded as sensitive and 5-6 as resistant.
Statistical analysis. The Mann-Whitney U-test was used for
unpaired comparisons. Survival curves were calculated by the
Kaplan-Meier method and compared by the log-rank test. The Cox
proportional hazards regression model was used in univariate
analysis. The significantly important factors were fitted together in
multivariate analysis in a backward stepwise manner using the
likelihood ratio test until all factors in the model were significant.
All reported p-values are two-sided, p<0.05 was considered as
statistically significant.
Results
Relapses after HSCT occurred in 15/44 children. The children
who relapsed after HSCT showed higher ex vivo resistance of
their leukemic blasts to fludarabine, treosulfan, etoposide,
mercaptopurine, thioguanine and mitoxantrone (Table I). No
significant differences were found for the other drugs. 
The overall probability of disease-free survival (pDFS) for
all 44 patients was 0.64±0.07, with a mean survival time of
2.7 years [95% confidence interval (CI)=2.1-3.3]. The type of
HSCT, disease status and age at transplantation had no
influence on the pDFS (Figure 1A-C). Better pDFS was
observed for patients ex vivo sensitive to fludarabine
(0.80±0.10 vs. 0.41±0.12, p=0.0184), thioguanine (0.81±0.09
vs. 0.44±0.11, p=0.0090), treosulfan (0.85±0.09 vs.
0.46±0.13, p=0.0368), etoposide (0.89±0.07 vs. 0.47±0.10,
p=0.0038), and for patients with a sensitive combined drug
resistance profile (FTE score) (0.91±0.08 vs. 0.46±0.12,
p=0.0221) (Figure 1D). 
Cell-biological features (age, sex, blast morphology, initial
leukocytosis, cytogenetics), response to therapy and drug
resistance profile parameters were taken together in the Cox
model. Out of all tested factors, those predicting positive
outcome by Cox univariate analysis were: ex vivo sensitivity to
fludarabine [p=0.036, hazard ratio (HR)=0.50, 95%CI=0.26-
0.95], etoposide (p=0.016, HR=0.40, 95%CI=0.19-0.85),
treosulfan (p=0.018, HR=0.46, 95%CI=0.24-0.87),
thioguanine (p=0.048, HR=0.59, 95%CI=0.21-0.97), and a
sensitive combined drug resistance profile discriminated by
FTE score (p=0.014, HR=0.44, 95%CI=0.18-0.83). No
factors showed prognostic value by multivariate analysis,
however the sensitive combined drug resistance profile
discriminated by FTE score was the strongest prognostic
factor (p=0.076, HR=0.39, 95%CI=0.13-1.10), though it was
possible to define the FTE score in only 33 out of 44 patients.
Discussion
The drug resistance profile identifies patients at higher risk
of treatment failure. In the study of Miller et al., which
included children and adults with ALL and AML, the
sensitivity of the occult leukemia colony-forming units to 
4-hydroperoxycyclophosphamide was the only factor that
predicted relapse following HSCT (8). In the present study,
the combined ex vivo drug resistance profile, although being
nondiscriminative, was the strongest prognostic factor in a
multivariate analysis for AML children undergoing HSCT.
No firm conclusions regarding the necessity for the use of
fludarabine, treosulfan and etoposide in the treatment of
AML with HSCT can be drawn from our study; however
these results might indicate that patients whose myeloblasts
are sensitive to fludarabine, treosulfan and etoposide would
benefit from the use of these drugs during conditioning
before HSCT, and possibly at the earlier stages of therapy.
Resistance to these drugs might suggest the necessity of
implementation of post-transplant procedures, such as close
monitoring of minimal residual disease, reduction of
immunosuppressive therapy, immunotherapy based on donor
lymphocyte infusion, or administration of interleukin-2. The
FTE score, however, could not prevent the overtreatment of
the patients with sensitive FTE scores, as all patients
qualifying for HSCT need very intensive therapy. 
AML is a relatively rare disease in children, however, the
results of therapy for this disease are still not satisfactory,
as only 50%-60% remission has been reported (11-14). The
value of testing sensitivity to fludarabine, treosulfan and
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etoposide in pediatric AML is related to the use of these
drugs which so far have not been tested (treosulfan) or not
widely tested (fludarabine). It has shown that these drugs
might have a role in the therapy of childhood AML (15),
especially treosulfan and fludarabine which have not really
been used as cytotoxic agents for AML but more as
biochemical modulators for cytarabine (16). 
In conclusion, ex vivo drug resistance to fludarabine,
treosulfan and etoposide is of predictive value in childhood
AML undergoing HSCT. Therefore, the drug resistance
profile may be used for better stratification of children with
AML indicating those patients who may be cured by
chemotherapy based on these drugs and to identify those
patients who are at high risk of treatment failure and who
Styczynski et al: Fludarabine, Treosulfan and Etoposide Sensitivity in AML
1549
Table I. Comparison of ex vivo drug resistance in patients staying in remission and relapsing after HSCT. The MTT assay was performed at AML
diagnosis, before HSCT was planned.
Drug (Company) Concentration IC50 (median and quartiles) RR p-value
[ÌM]
Remission Relapse 
Cytarabine 0.04-41 2.38 (n=28) 2.71 (n=15) 1.13 0.838
(Pharmacia Upjohn, Bentley, Australia) 0.57-9.66 1.35-5.13
Cladribine 0.001-140 0.26 (n=28) 0.24 (n=15) 0.94 0.508
(Bioton, Warsaw, Poland) 0.04-2.32 0.12-4.44
Fludarabine phosphate 0.05-54 2.16 (n=20) 8.68 (n=13) 4.01 0.036*
(Schering AG, Berlin, Germany) 0.87-8.15 3.25-33.1
Daunorubicin 0.002-3.5 1.01 (n=28) 1.25 (n=15) 1.24 0.177
(Rhone-Poulenc-Rhorer, Paris, France) 0.54-1.50 0.95-2.16
Doxorubicin 0.01-13.8 4.61 (n=22) 11.2 (n=12) 2.32 0.720
(Farmitalia, Milan, Italy) 1.31-13.8 1.56-13.8
Epirubicin 0.003-3.4 1.79 (n=20) 1.19 (n=11) 0.66 0.495
(Farmitalia, Milan, Italy) 0.93-3.13 0.75-2.51
Idarubicin 0.003-3.7 0.82 (n=27) 0.80 (n=15) 0.97 0.609
(Zavedos, Pharmacia, Milan, Italia) 0.35-1.53 0.39-1.12
Mitoxantrone 0.002-1.9 0.67 (n=18) 1.33 (n=11) 1.97 0.045*
(Jelfa, Jelenia Gora, Poland) 0.42-1.02 0.34-1.9
Etoposide 0.08-85 23.6 (n=28) 47.6 (n=14) 2.01 0.018*
(Bristol–Myers Squibb, Princeton, NJ, USA) 4.12-43.2 34.7-85
6-Thioguanine 9.3-299 45.9 (n=21) 130.9 (n=14) 2.84 0.006*
(Sigma, A4882, St. Louis, MO, USA) 25.6-103.8 79.2-299
6-Mercaptopurine 91-2937 418 (n=19) 1328 (n=14) 3.17 0.012*
(Sigma, M7000, St. Louis, MO, USA) 206-1038 629-1981
4-HOO-cyclophosphamide 0.3-341 6.85 (n=23) 10.6 (n=10) 1.55 0.153
(Asta Medica AG, Frankfurt/Main, Germany) 3.65-14.0 5.66-33.1
4-HOO-ifosfamide 0.33-341 59.0 (n=9) 64.9 (n=6) 1.10 0.679
(Asta Medica AG, Frankfurt/Main, Germany) 21.4-130.8 14.9-116.4
Mafosfamide 0.19-200 6.41 (n=23) 17.8 (n=10) 2.78 0.357
(Asta Medica AG, Frankfurt/Main, Germany) 2.37-17.6 4.49-18.9
Glufosfamide 0.5-522 66.8 (n=8) 51.3 (n=6) 0.76 0.697
(Asta Medica AG, Frankfurt/Main, Germany) 17.7-96.9 19.9-69.7
Treosulfan 0.002-3.6 0.006 (n=23) 0.077 (n=10) 12.6 0.020*
(Medac, Hamburg, Germany) 0.002-1.31 0.012-3.6
Melphalan 0.12-131 49.4 (n=14) 32.7 (n=5) 0.66 0.459
(Glaxo Wellcome, Parma, Italy) 20.0-58.6 12.6-74.7
Thiotepa Lederle 0.16-528 30.6 (n=18) 29.1 (n=7) 0.95 0.785
(Riemser, Greifswald, Germany) 11.4-47.8 18.3-42.9
Prednisolone 0.02- 694 303 (n=28) 304 (n=15) 1.00 0.452
(Jelfa, Jelenia Gora, Poland) 171-375 165-449
Vincristine 0.02-21 4.33 (n=28) 7.38 (n=15) 1.70 0.236
(Oncovin, Eli-Lilly, Indianapolis, IN, USA) 1.28-8.12 2.80-10.44
L-asparaginase 0.003-10 1.17 (n=29) 1.21 (n=15) 1.03 0.380
(Medac, Hamburg, Germany) 0.33-8.20 0.50-10.0
IC50: value of in vitro resistance, given in U/L for L-asparaginase and in mM for other drugs; RR: relative resistance = median IC50 (relapsed
AML) / median IC50 (remission AML); n: the number of patients; p-value: Mann-Whitney U-test; * significant differences between remission and
relapse.
therefore may benefit from more intensive treatment at
initial diagnosis, or require additional post-transplant
therapeutic strategies.
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